Updates to the Communicable Disease Control Manual

February 2021

Q fever and rickettsial diseases are now in separate chapters and have been updated.

The key changes to the Q fever chapter were:

  • updating information on laboratory testing for diagnosis, including updated criteria for laboratory definitive evidence and new criteria for laboratory suggestive evidence
  • updating information on management of contacts.

The key changes to the Rickettsial diseases chapter were:

  • updating information on laboratory testing for diagnosis, including updated criteria for laboratory definitive evidence and new criteria for laboratory suggestive evidence
  • updating the notification procedure.

Appendix 4 was also updated to include Section B laboratory notification of communicable diseases flowcharts and to add the meningoencephalitis – primary amoebic flowchart in Section A.

January 2021

We updated the Measles, Mumps and Rubella chapters and Appendix 4.

The key changes to the Measles chapter were:

  • adding throat swab as appropriate sample
  • incorporating the changes to the Immunisation Schedule and the changes to presumptive evidence of immunity.
  • updating algorithm for post-exposure MMR
  • noting that culture is no longer performed in NZ but is included as acceptable diagnostic test if used to diagnose overseas.

The key changes to the Mumps chapter were incorporating the changes to the Immunisation Schedule and updating references.

The key changes to the Rubella chapter were:

  • prophylaxis section – removing ‘post-exposure immunisation of non-pregnant women is recommended, especially if given within 3 days of exposure’
  • editing the information about immunising pregnant contacts and definition of protection.

Appendix 4 was updated to include Section A, Section C and other direct laboratory notification of communicable diseases flowcharts.

July 2020

We updated the Creutzfeldt-Jakob disease and other spongiform encephalopathies chapter.

The key changes include:

  • revision of notification procedure 
  • revision of clinical descriptions
  • revision of guidance on investigations for diagnosis
  • revised References and Further Information section.

We also updated the General considerations chapter to reflect the addition of novel coronavirus capable of causing severe respiratory illness (including COVID-19) to the list of notifiable diseases.

August 2019

We updated the Tuberculosis chapter to refer to the new Guidelines for Tuberculosis Control in New Zealand 2019.

May 2019

Updates were made to the VTEC/STEC chapter and Table 2.4 in Appendix 2.

Sections with more significant changes include:

  • Epidemiology in New Zealand: more detailed description provided
  • Clinical description turned into a clinical case definition 
  • Health education: more information provided
  • References and further information: more detailed references provided.

Sections with minor changes include:

  • Mode of transmission
  • Period of communicability
  • Investigation
  • Identification of source
  • Reporting.

March 2019

We added Appendix 4, which contains the direct laboratory notification diagram for HIV.

December 2018

The HIV and AIDS chapters were revised for clarity. This followed on from the update in October 2018 to incorporate the new HIV and AIDS notification system.

November 2018

Updates were made to the Mumps chapter. Serology testing has been deleted from the laboratory evidence in the case definition.

October 2018

Updates were made to the Neisseria meningitidis invasive disease chapter and case definitions for Syphilis and Gonorrhoea were added to the manual. The chapters for syphilis and gonorrohoea will be finalised alongside surveillance developments.

The key changes to the Neisseria meningitidis invasive disease chapter include include:

  • updates to the antimicrobials (ciprofloxacin) and immunisation (conjugate vaccines) sections
  • references and further information.

May 2018

Updates were made to the Measles chapter.

Sections with changes include:

  • Epidemiology in New Zealand
  • Mode of transmission 
  • Management of contacts
  • Incubation period
  • Infection control.

March 2018

Updates were made to the mumps and Neisseria meningitidis invasive disease chapters.

The key changes to the Mumps chapter include:

  • laboratory testing if no epidemiological link established
  • clarification about low value of mumps IgM and IgG serology testing.
  • clarification of the period of communicability used for contact tracing
  • correction of duplication and footnote numbering
  • references and further information.

For the Neisseria meningitidis invasive disease chapter, changes were made to the immunisation section to include information on how to access meningococcal B vaccine for a multi-occupancy residential meningococcal B outbreak.

A number of minor changes, to improve the clarity of the wording and the intent, were also made to the following chapters:

December 2017

A number of changes were made to the enteric chapters, in particular to the case definitions, clinical description and laboratory test for diagnosis sections.

The key changes are:

  • case definitions
  • clinical description
  • to reflect changes in diagnostic testing methods, changes have been made to the laboratory test for diagnosis section
  • case classification
  • appendix 1, 2 and 3 have amendments to legislation requirements and table 2.4: Exclusions and clearance criteria.

The Pertussis chapter was also updated. The key changes include:

  • updated objectives of surveillance for pertussis in the epidemiology in New Zealand section
  • clinical description changes to ‘A clinically compatible case characterised by a cough and one or more of paroxysms of cough; cough ending in vomiting, cyanosis or apnoea; inspiratory whoop’
  • case classification for ‘Probable’ changed to: ‘A clinically compatible illness where the cough is lasting longer than 2 weeks’
  • exclusion of cases can be shortened to 2 days if azithromycin is used
  • susceptible contacts should be given prophylaxis and not excluded while taking prophylaxis as long as they don’t have symptoms.

August 2017

An updated chapter on Poliomyelitis was published.

October 2017

An updated Invasive pneumococcal disease chapter was published to include changes to the case definition and section on laboratory tests for diagnosis.

July 2016

An updated Legionellosis chapter was published. The key changes in the new chapter are:

  • updates to the section on the clinical description of infection with Legionella
  • updates to the section on laboratory tests for diagnosis, including the addition of details about detection of Legionella species nucleic acid as a definitive laboratory evidence for a confirmed case.

December 2014

An updated Rheumatic fever chapter was published. The key changes in the new chapter are:

  • the removal of the requirement to notify Rheumatic Heart Disease under the age of 20
  • alignment of the case definitions to be consistent with the New Zealand Heart Foundation Guidelines and the EpiSurv case report form
  • the removal of the information relating to group A Streptococcus (GAS) to focus the chapter on Acute Rheumatic Fever (ARF)
  • the contact tracing section has been updated
  • information has been included on the notification of cases and the use of registers.
Back to top